BioNTech, OncoC4 collaborate on novel CTLA-4 antibody therapy
The collaboration aims to develop and market OncoC4’s monoclonal antibody candidate, ONC-392, as a standalone, or combination therapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Mar 23
The collaboration aims to develop and market OncoC4’s monoclonal antibody candidate, ONC-392, as a standalone, or combination therapy…
21 Mar 23
Designated as GS-6791, NX‑0479 is a bivalent degrader which is the first development candidate resulting from the previously…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
20 Mar 23
The contract development and manufacturing organisation (CDMO) intends to build Plant 5 at Bio Campus II, with a…
17 Mar 23
The FDA approval is based on results from the Phase 2/3 TADPOLE clinical trial, in which the combination…
16 Mar 23
The company will use the funding to advance its portfolio which comprises three novel antibody treatments that are…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Mar 23
With over 40% world market share, its presence spans Asia, Europe, the Middle East region and the U.S. KGC's family of brands…
15 Mar 23
Through our deep technical knowledge and long-standing experience in the agri/food industry, Sonata is well-positioned to help customers…
15 Mar 23
The Pfizer-BioNTech bivalent Covid-19 vaccine single booster dose is authorised for children as young as six months to…
15 Mar 23
The Rockford hub will have product testing capability, top-load cartoning technology, and injector and pen assembly equipment
14 Mar 23
The deal will add Provention Bio’s Tzield disease-modifying treatment for delay of Stage 3 type 1 diabetes to…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates